MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that (OSI) Prosidion, its UK subsidiary focused on the discovery and development of diabetes and obesity therapeutics, reported positive results from a metformin drug interaction study in healthy volunteers with its dipeptidyl peptidase-IV (DP-IV) inhibitor, PSN9301. Exposure to PSN9301 and metformin did not change to a clinically relevant extent when they were co-administered, compared with each therapy alone.
